These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38878679)

  • 1. Development of an in vitro assay for screening programmed death receptor-1/programmed cell death ligand 1 monoclonal antibody therapy in dogs.
    Mizuno T; Kato M; Tsukui T; Igase M
    Vet Immunol Immunopathol; 2024 Aug; 274():110792. PubMed ID: 38878679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of mouse anti-canine PD-L1 monoclonal antibodies and their expression in canine tumors by immunohistochemistry
    Sirivisoot S; Boonkrai C; Wongtangprasert T; Phakham T; Muanwein P; Pisitkun T; Sawangmake C; Radtanakatikanon A; Rungsipipat A
    Vet Q; 2023 Dec; 43(1):1-9. PubMed ID: 37477617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.
    Maekawa N; Konnai S; Takagi S; Kagawa Y; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Deguchi T; Nakajima C; Kato Y; Yamamoto K; Uemura H; Suzuki Y; Murata S; Ohashi K
    Sci Rep; 2017 Aug; 7(1):8951. PubMed ID: 28827658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function.
    Choi JW; Withers SS; Chang H; Spanier JA; De La Trinidad VL; Panesar H; Fife BT; Sciammas R; Sparger EE; Moore PF; Kent MS; Rebhun RB; McSorley SJ
    PLoS One; 2020; 15(7):e0235518. PubMed ID: 32614928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and characterization of monoclonal antibodies against canine PD-1 and PD-L1.
    Nemoto Y; Shosu K; Okuda M; Noguchi S; Mizuno T
    Vet Immunol Immunopathol; 2018 Apr; 198():19-25. PubMed ID: 29571514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells.
    Pandey MS; Wang C; Umlauf S; Lin S
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
    Fujiwara K; Shigematsu K; Tachibana M; Okada N
    IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of anti-feline PD-1 antibody and its functional analysis.
    Nishibori S; Kaneko MK; Nakagawa T; Nishigaki K; Kato Y; Igase M; Mizuno T
    Sci Rep; 2023 Apr; 13(1):6420. PubMed ID: 37095139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brusatol improves the efficacy of an anti-mouse-PD-1 antibody via inhibiting programmed cell death 1 ligand 1 expression in a murine head and neck squamous cell carcinoma model.
    Wu Y; Zhang G; Yin P; Wen J; Su Y; Zhang X
    Arch Oral Biol; 2024 Oct; 166():106043. PubMed ID: 38968906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astragalus membranaceus-Derived Anti-Programmed Death-1 Monoclonal Antibodies with Immunomodulatory Therapeutic Effects against Tumors.
    Chang FL; Tsai KC; Lin TY; Yang TW; Lo YN; Chen WC; Chang JH; Lu MK; Chiou CT; Chen PH; Yen Y; Pan SL; Lee YC
    Biomed Res Int; 2020; 2020():3415471. PubMed ID: 32190660
    [No Abstract]   [Full Text] [Related]  

  • 12. Sanguisorbae Radix Suppresses Colorectal Tumor Growth Through PD-1/PD-L1 Blockade and Synergistic Effect With Pembrolizumab in a Humanized PD-L1-Expressing Colorectal Cancer Mouse Model.
    Lee EJ; Kim JH; Kim TI; Kim YJ; Pak ME; Jeon CH; Park YJ; Li W; Kim YS; Choi JG; Chung HS
    Front Immunol; 2021; 12():737076. PubMed ID: 34659228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-Cell Engagers Based Bioassay for Evaluation of PD-1/PD-L1 Inhibitors Activity.
    Doronin AN; Gordeev AA; Kozlov AE; Smirnova YA; Puchkova MY; Ekimova VM; Basovskiy YI; Solovyev VV
    Biochemistry (Mosc); 2019 Jul; 84(7):711-719. PubMed ID: 31509723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1, PD-L1, and PD-L2 Gene Expression and Tumor Infiltrating Lymphocytes in Canine Melanoma.
    Stevenson VB; Perry SN; Todd M; Huckle WR; LeRoith T
    Vet Pathol; 2021 Jul; 58(4):692-698. PubMed ID: 34169800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative characterization of two monoclonal antibodies targeting canine PD-1.
    Kocikowski M; Dziubek K; Węgrzyn K; Hrabal V; Zavadil-Kokas F; Vojtesek B; Alfaro JA; Hupp T; Parys M
    Front Immunol; 2024; 15():1382576. PubMed ID: 38779661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
    Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
    Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
    Yoshimoto S; Chester N; Xiong A; Radaelli E; Wang H; Brillantes M; Gulendran G; Glassman P; Siegel DL; Mason NJ
    MAbs; 2023; 15(1):2287250. PubMed ID: 38047502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma.
    Maekawa N; Konnai S; Okagawa T; Nishimori A; Ikebuchi R; Izumi Y; Takagi S; Kagawa Y; Nakajima C; Suzuki Y; Kato Y; Murata S; Ohashi K
    PLoS One; 2016; 11(6):e0157176. PubMed ID: 27276060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.